These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 28062704)
1. Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei. Dillon MT; Barker HE; Pedersen M; Hafsi H; Bhide SA; Newbold KL; Nutting CM; McLaughlin M; Harrington KJ Mol Cancer Ther; 2017 Jan; 16(1):25-34. PubMed ID: 28062704 [TBL] [Abstract][Full Text] [Related]
2. ATR inhibition radiosensitizes cells through augmented DNA damage and G2 cell cycle arrest abrogation. Bright SJ; Manandhar M; Flint DB; Kolachina R; Ben Kacem M; Martinus DK; Turner BX; Qureshi I; McFadden CH; Marinello PC; Shaitelman SF; Sawakuchi GO JCI Insight; 2024 Oct; 9(19):. PubMed ID: 39235982 [TBL] [Abstract][Full Text] [Related]
3. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib. Wilson Z; Odedra R; Wallez Y; Wijnhoven PWG; Hughes AM; Gerrard J; Jones GN; Bargh-Dawson H; Brown E; Young LA; O'Connor MJ; Lau A Cancer Res; 2022 Mar; 82(6):1140-1152. PubMed ID: 35078817 [TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma. Odhiambo DA; Pittman AN; Rickard AG; Castillo RJ; Bassil AM; Chen J; Ravotti ML; Xu ES; Himes JE; Daniel AR; Watts TL; Williams NT; Luo L; Kirsch DG; Mowery YM Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1315-1327. PubMed ID: 38104870 [TBL] [Abstract][Full Text] [Related]
5. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239 [TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells. Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113 [TBL] [Abstract][Full Text] [Related]
7. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Bridges KA; Hirai H; Buser CA; Brooks C; Liu H; Buchholz TA; Molkentine JM; Mason KA; Meyn RE Clin Cancer Res; 2011 Sep; 17(17):5638-48. PubMed ID: 21799033 [TBL] [Abstract][Full Text] [Related]
8. The ATR Inhibitor AZD6738 Synergizes with Gemcitabine Wallez Y; Dunlop CR; Johnson TI; Koh SB; Fornari C; Yates JWT; Bernaldo de Quirós Fernández S; Lau A; Richards FM; Jodrell DI Mol Cancer Ther; 2018 Aug; 17(8):1670-1682. PubMed ID: 29891488 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer. Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066 [TBL] [Abstract][Full Text] [Related]
10. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721 [TBL] [Abstract][Full Text] [Related]
11. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer. Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721 [TBL] [Abstract][Full Text] [Related]
12. Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells. Isono M; Okubo K; Asano T; Sato A PLoS One; 2022; 17(4):e0266476. PubMed ID: 35413091 [TBL] [Abstract][Full Text] [Related]
13. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Sarcar B; Kahali S; Prabhu AH; Shumway SD; Xu Y; Demuth T; Chinnaiyan P Mol Cancer Ther; 2011 Dec; 10(12):2405-14. PubMed ID: 21992793 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy. Dunne V; Ghita M; Small DM; Coffey CBM; Weldon S; Taggart CC; Osman SO; McGarry CK; Prise KM; Hanna GG; Butterworth KT Radiother Oncol; 2017 Sep; 124(3):475-481. PubMed ID: 28697853 [TBL] [Abstract][Full Text] [Related]
15. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384. Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523 [TBL] [Abstract][Full Text] [Related]
16. AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells. Min A; Im SA; Jang H; Kim S; Lee M; Kim DK; Yang Y; Kim HJ; Lee KH; Kim JW; Kim TY; Oh DY; Brown J; Lau A; O'Connor MJ; Bang YJ Mol Cancer Ther; 2017 Apr; 16(4):566-577. PubMed ID: 28138034 [TBL] [Abstract][Full Text] [Related]
17. ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration. Fròsina G; Profumo A; Marubbi D; Marcello D; Ravetti JL; Daga A Radiat Oncol; 2018 Apr; 13(1):76. PubMed ID: 29685176 [TBL] [Abstract][Full Text] [Related]
18. CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy. Barker HE; Patel R; McLaughlin M; Schick U; Zaidi S; Nutting CM; Newbold KL; Bhide S; Harrington KJ Mol Cancer Ther; 2016 Sep; 15(9):2042-54. PubMed ID: 27422809 [TBL] [Abstract][Full Text] [Related]
19. ATR inhibition sensitizes HPV Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392 [TBL] [Abstract][Full Text] [Related]
20. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Morgan MA; Parsels LA; Zhao L; Parsels JD; Davis MA; Hassan MC; Arumugarajah S; Hylander-Gans L; Morosini D; Simeone DM; Canman CE; Normolle DP; Zabludoff SD; Maybaum J; Lawrence TS Cancer Res; 2010 Jun; 70(12):4972-81. PubMed ID: 20501833 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]